Zoetis Inc. (ZTS) Aandelenanalyse

Bedrijfsoverzicht

Zoetis Inc. is a leading global entity dedicated to the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which signifies a focus on specialized pharmaceutical products distinct from mass-market consumer drugs. Zoetis Inc. commands a substantial market presence with a market capitalization of $49.75B, generating annual revenue (TTM) of $9.47B, and employs a workforce of 14500 individuals across its operations. These valuation and revenue figures indicate that the company holds a dominant position within its niche, reflecting significant market trust and a robust scale that allows for substantial investment in research and development while maintaining a large operational footprint globally.

Financiële gezondheid

The company reported a revenue (TTM) of $9.47B, with a net income (TTM) of $2.67B and an EBITDA of $4.07B, illustrating a clear gap between total revenue and net income that reveals a substantial cost structure comprising operating expenses, taxes, and interest. Zoetis generates a free cash flow of $1.79B, which provides the organization with significant financial flexibility to fund capital expenditures, pursue strategic acquisitions, or manage working capital needs without relying heavily on external financing. The firm demonstrates strong profitability efficiency with a gross margin of 71.9%, an operating margin of 34.7%, and a profit margin of 28.2%, where the high gross margin indicates strong pricing power and low cost of goods sold, while the operating and profit margins reflect effective cost control and operational leverage. On the liability side, the company holds $2.31B in cash against $9.31B in debt, resulting in a debt-to-equity ratio of 279.59, which suggests a highly leveraged balance sheet typical for capital-intensive pharmaceutical firms but requiring careful interest management. Liquidity is robust as evidenced by a current ratio of 3.03, indicating that the company possesses more than three times the current assets necessary to cover its short-term liabilities, ensuring it can meet obligations comfortably. Management effectiveness is highlighted by a return on equity of 66.0% and a return on assets of 15.3%, metrics that demonstrate an exceptional ability to generate returns on shareholder investments and utilize its asset base efficiently to drive value.

Waarderingsbeoordeling

Zoetis Inc. is valued with a P/E Ratio (TTM) of 19.58 and a Forward P/E of 15.61, and the difference between these two metrics implies that the market expects earnings to grow in the coming year, allowing the forward multiple to be lower than the trailing multiple. The price-to-book ratio stands at 15.04, which indicates that the market prices the company at a significant premium over its book value, reflecting the high intangible asset value inherent in intellectual property and brand strength within the pharmaceutical sector. Alternative valuation metrics such as a price-to-sales ratio of 5.26 and an EV/EBITDA of 13.96 suggest that investors are willing to pay a high multiple for revenue and earnings, consistent with the high-margin nature of specialty drug manufacturing. Price volatility and trading range are defined by a 52-Week High of $172.23 and a 52-Week Low of $113.29, meaning the current share price sits somewhere within this historical range, bounded by recent market peaks and troughs. The stock exhibits a beta of 0.97, which indicates that the price volatility of Zoetis moves in close alignment with the broader market, showing slightly less sensitivity to market swings than a beta of 1.0 would imply.

Growth & Income

Zoetis Inc. is experiencing a revenue growth (YoY) of 3.0% and an earnings growth (YoY) of 6.1%, where earnings are growing faster than revenue, which implies that the company is improving its operational efficiency and margin expansion capabilities to outpace top-line volume growth. As a dividend payer, the company offers a dividend yield of 1.8% with a payout ratio of 33.2%, indicating that the payout is highly sustainable given the company's strong earnings growth and substantial free cash flow generation. The relatively low payout ratio suggests that Zoetis retains a significant portion of its earnings to reinvest in its pipeline and R&D rather than distributing the maximum possible amount to shareholders immediately. Overall, the growth and income profile characterizes Zoetis as a mature specialty pharmaceutical company that balances modest but reliable dividend income with double-digit earnings growth driven by margin optimization rather than purely by revenue expansion.